Investment analysts at Jefferies Financial Group assumed coverage on shares of Akero Therapeutics (NASDAQ:AKRO) in a research note issued to investors on Monday, MarketBeat Ratings reports. The brokerage set a “buy” rating and a $28.00 price target on the stock. Jefferies Financial Group’s target price points to a potential upside of 36.39% from the stock’s previous close.
AKRO has been the subject of a number of other research reports. JPMorgan Chase & Co. reissued a “sell” rating and issued a $18.00 price objective on shares of ABB in a report on Monday. Roth Capital reissued a “buy” rating on shares of Coeur Mining in a report on Monday.
Shares of NASDAQ AKRO opened at $20.53 on Monday. Akero Therapeutics has a 52 week low of $16.06 and a 52 week high of $21.94.
About Akero Therapeutics
Akero Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development and commercialization of transformative treatments for serious metabolic diseases with high unmet medical need. Its lead product candidate is AKR-001, which completed Phase Ib clinical trial for the treatment of non-alcoholic steatohepatitis disease.
Recommended Story: What does it mean to hold a stock in street name?
Receive News & Ratings for Akero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.